Finance

Roʻyxatlar
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
98,10 R$
0,00%
(0,00) 1K
7-okt, 13:35:03 (GMT-3)  ·   BRL
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
T1EV34 tikeri uchun statistika yaratilmoqda...
Bozor kapitali
45,00 mlrd
Oʻrtacha hajm
127,00
Hajmi
0,00
52 haftalik eng yuqori
101,90 R$
52 haftalik eng past
51,60 R$
Muomaladagi aksiyalar
1,17 mlrd
Xodimlar soni
32 ming
Bozor kapitali
45,00 mlrd
Oʻrtacha hajm
127,00
Hajmi
0,00
52 haftalik eng yuqori
101,90 R$
52 haftalik eng past
51,60 R$
Muomaladagi aksiyalar
1,17 mlrd
Xodimlar soni
32 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
Teva Pharmaceutical Industries Bdr haqida
CEORichard Francis
Xodimlar soni32 ming
Asos solingan13-fev, 1944
Bosh ofislar-
Sektor-
Veb-saytteva.co.il
Oxirgi hisobot
29-iyl, 2026
Moliya davri
Ch.2 2026
0,02 US$ / 0,11 US$
-81,46%manfiy
Taxminiy daromad (USD)
4,14 mlrd / 4,03 mlrd
+2,79%musbat
Q2 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
4,48 mlrd
4,71 mlrd
3,98 mlrd
4,14 mlrd
Sotilgan mahsulotning tannarxi
2,18 mlrd
2,06 mlrd
2,01 mlrd
1,99 mlrd
Daromad narxi
2,18 mlrd
2,06 mlrd
2,01 mlrd
1,99 mlrd
Tadqiqot va ishlanmalarga xarajatlar
256,00 mln
267,00 mln
222,00 mln
970,00 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
973,00 mln
1,12 mlrd
1,00 mlrd
1,03 mlrd
Operatsion xarajatlar
1,24 mlrd
1,37 mlrd
1,21 mlrd
1,99 mlrd
Jami operatsion xarajatlar
3,41 mlrd
3,43 mlrd
3,22 mlrd
3,98 mlrd
Operatsion daromad
1,07 mlrd
1,28 mlrd
763,00 mln
167,00 mln
Boshqa nooperatsion daromad
-27,00 mln
-
-13,00 mln
-69,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
648,00 mln
90,00 mln
436,00 mln
-455,00 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
832,00 mln
1,08 mlrd
547,00 mln
-57,00 mln
Daromad soligʻi boʻyicha xarajat
214,00 mln
-390,00 mln
67,00 mln
121,00 mln
Amaldagi soliq stavkasi
33,02%
-433,33%
15,37%
-26,59%
Boshqa operatsion xarajatlar
9,00 mln
-17,00 mln
-14,00 mln
-18,00 mln
Sof foyda
433,00 mln
480,00 mln
369,00 mln
-576,00 mln
Sof foyda marjasi
9,67%
10,19%
9,27%
-13,91%
Har bir aksiya foydasi
0,78
0,96
0,53
0,02
Foizlar va investitsiyalardan olingan daromadlar
-
92,00 mln
-
-
Foizlarni toʻlash xarajatlari
-205,00 mln
-280,00 mln
-191,00 mln
-186,00 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-205,00 mln
-188,00 mln
-191,00 mln
-186,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
1,32 mlrd
1,54 mlrd
1,00 mlrd
408,00 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-8,00 mln
-12,00 mln
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari